» Articles » PMID: 18390729

Unique Effects of KIT D816V in BaF3 Cells: Induction of Cluster Formation, Histamine Synthesis, and Early Mast Cell Differentiation Antigens

Abstract

Oncogenic tyrosine kinases (TK) usually convert growth factor-dependent cells to factor independence with autonomous proliferation. However, TK-driven neoplasms often are indolent and characterized by cell differentiation rather than proliferation. A prototype of an indolent TK-driven neoplasm is indolent systemic mastocytosis. We found that the D816V-mutated variant of KIT, a TK detectable in most patients with systemic mastocytosis, induces cluster formation and expression of several mast cell differentiation and adhesion Ags, including microphthalmia transcription factor, IL-4 receptor, histamine, CD63, and ICAM-1 in IL-3-dependent BaF3 cells. By contrast, wild-type KIT did not induce cluster formation or mast cell differentiation Ags. Additionally, KIT D816V, but not wild-type KIT, induced STAT5 activation in BaF3 cells. However, despite these intriguing effects, KIT D816V did not convert BaF3 cells to factor-independent proliferation. Correspondingly, BaF3 cells with conditional expression of KIT D816V did not form tumors in nude mice. Together, the biologic effects of KIT D816V in BaF3 cells match strikingly with the clinical course of indolent systemic mastocytosis and with our recently established transgenic mouse model, in which KIT D816V induces indolent mast cell accumulations but usually does not induce a malignant mast cell disease. Based on all these results, it is hypothesized that KIT D816V as a single hit may be sufficient to cause indolent systemic mastocytosis, whereas additional defects may be required to induce aggressive mast cell disorders.

Citing Articles

Unraveling the Rare Entity of D816V-Negative Systemic Mastocytosis.

Alyamany R, Albachir C, Alsaleh S, Hamad A, Abdulwali S, Alotaibi A J Hematol. 2024; 13(3):128-136.

PMID: 38993735 PMC: 11236357. DOI: 10.14740/jh1279.


CRISPR/Cas9-engineering of HMC-1.2 cells renders a human mast cell line with a single D816V-KIT mutation: An improved preclinical model for research on mastocytosis.

Bandara G, Falduto G, Luker A, Bai Y, Pfeiffer A, Lack J Front Immunol. 2023; 14:1078958.

PMID: 37025992 PMC: 10071028. DOI: 10.3389/fimmu.2023.1078958.


SETD2 non genomic loss of function in advanced systemic mastocytosis is mediated by an Aurora kinase A/MDM2 axis and can be therapeutically targeted.

Mancini M, Monaldi C, De Santis S, Papayannidis C, Rondoni M, Sartor C Biomark Res. 2023; 11(1):29.

PMID: 36894973 PMC: 9999558. DOI: 10.1186/s40364-023-00468-7.


New Insights into the Pathogenesis of Systemic Mastocytosis.

Li Z Int J Mol Sci. 2021; 22(9).

PMID: 34063170 PMC: 8125314. DOI: 10.3390/ijms22094900.


Delineation of target expression profiles in CD34+/CD38- and CD34+/CD38+ stem and progenitor cells in AML and CML.

Herrmann H, Sadovnik I, Eisenwort G, Rulicke T, Blatt K, Herndlhofer S Blood Adv. 2020; 4(20):5118-5132.

PMID: 33085758 PMC: 7594398. DOI: 10.1182/bloodadvances.2020001742.


References
1.
Fritsche-Polanz R, Jordan J, Feix A, Sperr W, Sunder-Plassmann G, Valent P . Mutation analysis of C-KIT in patients with myelodysplastic syndromes without mastocytosis and cases of systemic mastocytosis. Br J Haematol. 2001; 113(2):357-64. DOI: 10.1046/j.1365-2141.2001.02783.x. View

2.
Valent P, Horny H, Escribano L, Longley B, Li C, Schwartz L . Diagnostic criteria and classification of mastocytosis: a consensus proposal. Leuk Res. 2001; 25(7):603-25. DOI: 10.1016/s0145-2126(01)00038-8. View

3.
Mayerhofer M, Florian S, Krauth M, Aichberger K, Bilban M, Marculescu R . Identification of heme oxygenase-1 as a novel BCR/ABL-dependent survival factor in chronic myeloid leukemia. Cancer Res. 2004; 64(9):3148-54. DOI: 10.1158/0008-5472.can-03-1200. View

4.
Klucher K, Lopez D, Daley G . Secondary mutation maintains the transformed state in BaF3 cells with inducible BCR/ABL expression. Blood. 1998; 91(10):3927-34. View

5.
Escribano L, Bellas C, Navalon R, Nunez R, Sperr W, Schernthaner G . Utility of flow cytometric analysis of mast cells in the diagnosis and classification of adult mastocytosis. Leuk Res. 2001; 25(7):563-70. DOI: 10.1016/s0145-2126(01)00050-9. View